For neuroendocrine neoplasms, the newest guideline from the WHO classification emphasizes the importance of Ki67 in classification and grading,7 and it has been determined to be an independent risk prognostic marker in high‐grade neuroendocrine tumours and carcinomas, which typically exhibit highly aggressive and advanced stages.8 The gene discussed is MKI67; the disease is neuroendocrine neoplasm.